AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7867830 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical acyclovir ointment, 5 times daily for 7 days
Number of subjects: 57
Study 7867830 — intervention group
Group type: COMPARATOR
Intervention: Oral acyclovir, 800 mg, 5 times daily for 7 days
Number of subjects: 57
Study 2760908 — intervention group
Group type: EXPERIMENTAL
Intervention: Borage oil (containing 18:3n‐6)
Number of subjects: 30
Study 2760908 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (containing 20:5n‐3)
Number of subjects: 30
Study 2760908 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (placebo)
Number of subjects: 30
Study 1272683 — intervention group
Group type: EXPERIMENTAL
Intervention: Affective social reinforcement condition ("good-fine")
Number of subjects: 40
Study 1272683 — intervention group
Group type: EXPERIMENTAL
Intervention: Informative social reinforcement condition ("correct-right")
Number of subjects: 40
Study 1272683 — intervention group
Group type: EXPERIMENTAL
Intervention: Rule-governed imitation
Number of subjects: 40
Study 1272683 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforcement administered on a fixed ratio (FR4) schedule
Number of subjects: 40
Study 29985719 — intervention group
Group type: EXPERIMENTAL
Intervention: BEMER therapy combined with rehabilitation for 10 consecutive days
Number of subjects: 30
Study 29985719 — intervention group
Group type: COMPARATOR
Intervention: Sham BEMER treatment combined with rehabilitation
Number of subjects: 30
Study 30971301 — intervention group
Group type: EXPERIMENTAL
Intervention: Definitive concurrent chemoradiotherapy (DCRT) with intensity-modulated radiation therapy (IMRT) at 50 Gy/25 fractions and basic chemotherapy with 5-fluorouracil regimens
Number of subjects: 196
Study 30971301 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant chemoradiotherapy (NCRT) followed by standard oesophagectomy
Number of subjects: 196
Study 30971301 — intervention group
Group type: EXPERIMENTAL
Intervention: Definitive concurrent chemoradiotherapy (DCRT)
Number of subjects: 196
Study 28536825 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular clodronate (CLO) 200 mg/day i.m. for 10 days, followed by 200 mg/day i.m. for 6 days after 3 and 6 months, added to usual NSAIDs or analgesic drugs.
Number of subjects: 40
Study 28536825 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment with anti-inflammatory or analgesic drugs (Control Group B).
Number of subjects: 40
Study 26115797 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus bevacizumab (7.5 mg/kg every 3 weeks, continued with up to 12 further cycles)
Number of subjects: 1528
Study 26115797 — intervention group
Group type: COMPARATOR
Intervention: Standard chemotherapy (six 3-weekly cycles of intravenous carboplatin [AUC 5 or 6] and paclitaxel 175 mg/m2)
Number of subjects: 1528
Study 26115797 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus bevacizumab (in poor prognosis subgroup)
Number of subjects: 1528
Study 26115797 — intervention group
Group type: COMPARATOR
Intervention: Standard chemotherapy (in poor prognosis subgroup)
Number of subjects: 1528
Study 26115797 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus bevacizumab (in non-high-risk patients)
Number of subjects: 1528
Study 26115797 — intervention group
Group type: COMPARATOR
Intervention: Standard chemotherapy (in non-high-risk patients)
Number of subjects: 1528
Study 23631112 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental tooth clenching at 10%, 20%, or 40% of maximal voluntary clenching force (MVCF) for 60 minutes with follow-ups at 24 and 48 hours.
Number of subjects: 76
Study 23631112 — intervention group
Group type: COMPARATOR
Intervention: 20-minute repetitive experimental tooth clenching task at 50% of MVCF.
Number of subjects: 76
Study 23631112 — intervention group
Group type: COMPARATOR
Intervention: Experimental tooth clenching in patients with M‐TMD.
Number of subjects: 76
Study 21135703 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanyl (n=50)
Number of subjects: 100
Study 21135703 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (n=50)
Number of subjects: 100
Study 19101777 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual users of VA and non-VA care
Number of subjects: 550
Study 19101777 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual users of physical health services
Number of subjects: 550
Study 19101777 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual users of emotional health services
Number of subjects: 550
Study 19101777 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with dual use
Number of subjects: 550
Study 17848651 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (low-dose: 0.2 mg/kg per dose if weight <62.5 kg or 12.5 mg per dose if weight >=62.5 kg; high-dose: 0.4 mg/kg per dose if weight <62.5 kg or 25 mg per dose if weight >=62.5 kg)
Number of subjects: 161
Study 17848651 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study 17848651 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined carvedilol group
Number of subjects: 161
Study 17848651 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 161
Study 15545293 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound screening
Number of subjects: 41000
Study 15545293 — intervention group
Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 41000
Study 15545293 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound screening (aged 65-75)
Number of subjects: 41000
Study 11281561 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha treatment
Number of subjects: 404
Study 11281561 — intervention group
Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 404
Study 11281561 — intervention group
Group type: COMPARATOR
Intervention: Baseline cirrhosis
Number of subjects: 404
Study 11281561 — intervention group
Group type: COMPARATOR
Intervention: Age comparison
Number of subjects: 404
Study 9441075 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG immunization
Number of subjects: 33
Study 9441075 — intervention group
Group type: COMPARATOR
Intervention: Control (non-immunized infants)
Number of subjects: 33
Study 8470032 — intervention group
Group type: COMPARATOR
Intervention: FGR (BACOP, COPP, CHOP, CNOP)
Number of subjects: 449
Study 8470032 — intervention group
Group type: EXPERIMENTAL
Intervention: CAVPE
Number of subjects: 449
Study 8470032 — intervention group
Group type: COMPARATOR
Intervention: FGR
Number of subjects: 449
Study 3546612 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumpectomy/radiation
Number of subjects: 75
Study 3546612 — intervention group
Group type: COMPARATOR
Intervention: Combination chemotherapy (Adriamycin plus Cytoxan or methotrexate plus 5-FU)
Number of subjects: 75
Study 3546612 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline distress factors (fatigue/depression, lack of social support)
Number of subjects: 75
Study 30060770 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced disinfection strategies for terminal room disinfection
Number of subjects: 0
Study 30060770 — intervention group
Group type: COMPARATOR
Intervention: Standard practice disinfection
Number of subjects: 0
Study 27430587 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive low-calorie meal replacement diet (ILCD, 960 kcal/day)
Number of subjects: 28
Study 27430587 — intervention group
Group type: COMPARATOR
Intervention: Balanced deficit diet (BDD, 500 kcal/day below estimated energy needs)
Number of subjects: 28
Study 27430587 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (ILCD and BDD)
Number of subjects: 28
Study 24456998 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-modal intervention (specific clinical targets, education, diet, and resistance training exercise)
Number of subjects: 1718
Study 24456998 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1718
Study 22327088 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (268 mg·d⁻¹)
Number of subjects: 12
Study 22327088 — intervention group
Group type: COMPARATOR
Intervention: Placebo (glucose: 30 mg·d⁻¹)
Number of subjects: 12
Study 22327088 — intervention group
Group type: EXPERIMENTAL
Intervention: Training
Number of subjects: 12
Study 20121752 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 44
Study 20121752 — intervention group
Group type: COMPARATOR
Intervention: Continuation of original immunosuppression
Number of subjects: 44
Study 18030229 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 0.25 mg/kg
Number of subjects: 50
Study 18030229 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 1 mg/kg
Number of subjects: 50
Study 16102683 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol TCI (Diprifusor pharmacokinetic model) starting at 4 microg/mL, adjusted by 0.4 microg/mL step size
Number of subjects: 60
Study 12120768 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-filled flowable restorative material (CuRay-Match)
Number of subjects: 32
Study 12120768 — intervention group
Group type: COMPARATOR
Intervention: Unfilled sealant (Delton)
Number of subjects: 32
Study 10231510 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microg recombinant human platelet‐derived growth factor‐BB daily
Number of subjects: 83
Study 10231510 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 microg recombinant human platelet‐derived growth factor‐BB daily
Number of subjects: 83
Study 10231510 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microg recombinant human platelet‐derived growth factor‐BB bid
Number of subjects: 83
Study 10231510 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 7503191 — intervention group
Group type: EXPERIMENTAL
Intervention: Home uterine activity monitoring
Number of subjects: 0
Study 7503191 — intervention group
Group type: EXPERIMENTAL
Intervention: Home uterine activity monitoring (singleton pregnancies)
Number of subjects: 0
Study 7503191 — intervention group
Group type: EXPERIMENTAL
Intervention: Home uterine activity monitoring (twin pregnancies)
Number of subjects: 0
Study 1348481 — intervention group
Group type: EXPERIMENTAL
Intervention: celiprolol 400 mg
Number of subjects: 10
Study 1348481 — intervention group
Group type: COMPARATOR
Intervention: propranolol 40 mg
Number of subjects: 10
Study 1348481 — intervention group
Group type: EXPERIMENTAL
Intervention: celiprolol 400 mg plus propranolol 40 mg
Number of subjects: 10
Study 1348481 — intervention group
Group type: COMPARATOR
Intervention: placebo plus propranolol 40 mg
Number of subjects: 10
Study 2860740 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (325 mg) plus Persantine (75 mg) four times daily
Number of subjects: 890
Study 2860740 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (325 mg) plus placebo
Number of subjects: 890
Study 28567529 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-bow registration
Number of subjects: 32
Study 28567529 — intervention group
Group type: COMPARATOR
Intervention: Mean settings with Bonwill triangle and Balkwill angle
Number of subjects: 32
Study 27717210 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF + CMX (xenogeneic collagen matrix)
Number of subjects: 45
Study 27717210 — intervention group
Group type: COMPARATOR
Intervention: CAF (coronally advanced flap)
Number of subjects: 45
Study 26336072 — intervention group
Group type: EXPERIMENTAL
Intervention: General information about heart disease and written advice to attend their GP for CVD risk assessment
Number of subjects: 97
Study 26336072 — intervention group
Group type: COMPARATOR
Intervention: General information about heart disease only
Number of subjects: 97
Study 23922470 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-balloon colonoscopy (SBC)
Number of subjects: 21
Study 23922470 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-balloon colonoscopy (DBC)
Number of subjects: 21
Study 23922470 — intervention group
Group type: COMPARATOR
Intervention: Control (Conventional colonoscopy)
Number of subjects: 21
Study 21670714 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean ICP wave amplitude (MWA) guided intensive care management
Number of subjects: 97
Study 21670714 — intervention group
Group type: COMPARATOR
Intervention: Mean ICP management (less than 20 mm Hg)
Number of subjects: 97
Study 18797149 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQ10
Number of subjects: 11
Study 18797149 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 17369904 — intervention group
Group type: EXPERIMENTAL
Intervention: Poetam (affinity‐purified antibodies to recombinant human erythropoietin) combined with iron preparation
Number of subjects: 0
Study 17369904 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy with Poetam
Number of subjects: 0
Study 17369904 — intervention group
Group type: COMPARATOR
Intervention: Sorbifer (iron preparation)
Number of subjects: 0
Study 14669170 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramlintide (120 microg twice daily or 150 microg 3 times a day)
Number of subjects: 410
Study 14669170 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramlintide
Number of subjects: 410
Study 14669170 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 410
Study 11271081 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose hydrocortisone therapy (100 mg bolus, 10 mg/h for 7 days and subsequent tapering)
Number of subjects: 20
Study 11271081 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose hydrocortisone therapy
Number of subjects: 20
Study 8830301 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (5 mg, p.o.)
Number of subjects: 8
Study 8830301 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 2368376 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-to-moderate-intensity walking program (mean 69% of maximal heart rate), 40-45 minutes, three times per week for two months.
Number of subjects: 16
Study 2368376 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise intervention).
Number of subjects: 16
Study 110129 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential amino acids plus arginine and histidine infusion
Number of subjects: 6
Study 110129 — intervention group
Group type: COMPARATOR
Intervention: General amino acid solution infusion
Number of subjects: 6
Study 29788823 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic supplementation
Number of subjects: 49
Study 29788823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 29788823 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 49
Study 30866485 — intervention group
Group type: EXPERIMENTAL
Intervention: Skate skin collagen peptides (SCP) 2000 mg per day for 12 weeks
Number of subjects: 90
Study 30866485 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 27869986 — intervention group
Group type: EXPERIMENTAL
Intervention: AD + PE (sertraline plus physical exercise)
Number of subjects: 121
Study 27869986 — intervention group
Group type: COMPARATOR
Intervention: AD (sertraline)
Number of subjects: 121
Study 26887210 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation group (n=48)
Number of subjects: 145
Study 26887210 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine acupuncture group (n=49)
Number of subjects: 145
Study 26887210 — intervention group
Group type: EXPERIMENTAL
Intervention: Para-BL10 group (n=48)
Number of subjects: 145
Study 24021323 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqueous liquorice mouthwash (15%)
Number of subjects: 60
Study 24021323 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanolic liquorice mouthwash (3.75%)
Number of subjects: 60
Study 24021323 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine gluconate (0.156%)
Number of subjects: 60
Study 22044549 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Coordination Training (PCT)
Number of subjects: 294
Study 22044549 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Training (CBTr)
Number of subjects: 294
Study 22044549 — intervention group
Group type: COMPARATOR
Intervention: Reference Group (REF)
Number of subjects: 294
Study 19447358 — intervention group
Group type: EXPERIMENTAL
Intervention: GSH/MI treatment (6 guided self-help sessions and 2 sessions utilizing an MI approach)
Number of subjects: 39
Study 19447358 — intervention group
Group type: COMPARATOR
Intervention: GSH treatment (6 sessions of traditional guided self-help and 2 traditional motivation-focused sessions)
Number of subjects: 39
Study 16822117 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic-based cognitive-behavior therapy
Number of subjects: 72
Study 16822117 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic-plus-Internet cognitive-behavior therapy
Number of subjects: 72
Study 16822117 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (WL)
Number of subjects: 72
Study 12918634 — intervention group
Group type: EXPERIMENTAL
Intervention: Keep on Talking program (experimental group)
Number of subjects: 250
Study 12918634 — intervention group
Group type: COMPARATOR
Intervention: Communication assessment (control group)
Number of subjects: 250
Study 12918634 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Communication Education program (preliminary outcomes, n = 14)
Number of subjects: 250
Study 11775909 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen group (19 cases)
Number of subjects: 52
Study 11775909 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen plus progesterone group (23 cases)
Number of subjects: 52
Study 11775909 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (10 cases)
Number of subjects: 52
Study 11775909 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 healthy premenopausal women)
Number of subjects: 52
Study 9099388 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumethasone (10 mg)
Number of subjects: 45
Study 9099388 — intervention group
Group type: EXPERIMENTAL
Intervention: Dinoprost (25 mg)
Number of subjects: 45
Study 9099388 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (Control)
Number of subjects: 45
Study 8344093 — intervention group
Group type: COMPARATOR
Intervention: Bowel lavage with polyethylene glycol electrolyte solution (Colyte) after 2 g acetaminophen dose
Number of subjects: 19
Study 8344093 — intervention group
Group type: COMPARATOR
Intervention: Bowel lavage with polyethylene glycol electrolyte solution (Colyte) after 4 g acetaminophen dose
Number of subjects: 19
Study 8344093 — intervention group
Group type: COMPARATOR
Intervention: Activated charcoal after 4 g acetaminophen dose
Number of subjects: 19
Study 3325490 — intervention group
Group type: EXPERIMENTAL
Intervention: 27-h fast
Number of subjects: 9
Study 3325490 — intervention group
Group type: COMPARATOR
Intervention: Preexercise meal
Number of subjects: 9
Study 29243031 — intervention group
Group type: COMPARATOR
Intervention: High-dose cytarabine (HiDAC)
Number of subjects: 240
Study 29243031 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation (ASCT)
Number of subjects: 240
Study 27650788 — intervention group
Group type: EXPERIMENTAL
Intervention: Average weight version of patient information materials
Number of subjects: 64
Study 27650788 — intervention group
Group type: COMPARATOR
Intervention: Standard patient information version on confidence intervals (control group)
Number of subjects: 64
Study 24245978 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,064 nm Q-Switched Nd:YAG laser plus chemical peeling with Jessner's solution (Group B)
Number of subjects: 52
Study 24245978 — intervention group
Group type: COMPARATOR
Intervention: 1,064 nm Q-Switched Nd:YAG laser plus placebo chemical peeling (Group A)
Number of subjects: 52
Study 24245978 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 52
Study 23734252 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea (OSA) as determined by a portable device
Number of subjects: 96
Study 23734252 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea (OSA)
Number of subjects: 96
Study 19937457 — intervention group
Group type: EXPERIMENTAL
Intervention: Balneotherapy in mineral water
Number of subjects: 42
Study 19937457 — intervention group
Group type: COMPARATOR
Intervention: Tap water (control)
Number of subjects: 42
Study 18320806 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery alone for thoracic esophageal cancer
Number of subjects: 0
Study 18320806 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant chemotherapy
Number of subjects: 0
Study 18320806 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 0
Study 15920347 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose induction interferon (10 MU daily for the first week) plus ribavirin (1,000 mg/day for 24 weeks) - HR group (n = 29)
Number of subjects: 59
Study 15920347 — intervention group
Group type: COMPARATOR
Intervention: Conventional combination therapy (3 MU interferon three times weekly plus ribavirin 1,000 mg/day for 24 weeks) - CR group (n = 30)
Number of subjects: 59
Study 14629854 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese acupuncture
Number of subjects: 1062
Study 14629854 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 1062
Study 14629854 — intervention group
Group type: COMPARATOR
Intervention: Conventional standard therapy
Number of subjects: 1062
Study 10376459 — intervention group
Group type: EXPERIMENTAL
Intervention: Water intubation technique
Number of subjects: 100
Study 10376459 — intervention group
Group type: COMPARATOR
Intervention: Traditional method
Number of subjects: 100
Study 8669100 — intervention group
Group type: EXPERIMENTAL
Intervention: FK506 (0.2 mg/kg/day)
Number of subjects: 120
Study 8669100 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 120
Study 8669100 — intervention group
Group type: EXPERIMENTAL
Intervention: FK506
Number of subjects: 120
Study 1839993 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol hydrobromide (200 micrograms)
Number of subjects: 20
Study 1839993 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (40 micrograms)
Number of subjects: 20
Study 1839993 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of fenoterol and ipratropium bromide (200 micrograms and 40 micrograms respectively)
Number of subjects: 20
Study 6481115 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose
Number of subjects: 32
Study 6481115 — intervention group
Group type: COMPARATOR
Intervention: Sucrose
Number of subjects: 32